MADISON, Wis., Jan. 8, 2026 /PRNewswire/ -- Elephas Biosciences Corporation (Elephas), a private company that has developed an innovative live tissue platform for immunotherapy response prediction, ...
Elephas, an oncology-focused diagnostics platform, announced it secured $55 million in Series C funding, bringing its total raise to $116.5 million. Venture Investors Health Fund and the State of ...
ELEPHAS BIOSCIENCES RAISES $40M TO ACCELERATE COMMERCIALIZATION OF ITS LIVE TUMOR PROFILING PLATFORM
MADISON, Wis., Nov. 6, 2025 /PRNewswire/ -- Elephas Biosciences Corporation (Elephas), a private company that has developed an innovative live tumor profiling platform for immunotherapy response ...
Madison-based Elephas Biosciences Corp. announced Monday the completion of a $41.5 million Series B funding round. The round was led by Chicago-based ARCH Venture Partners with continued investment by ...
Arch Venture Partners leads round to advance company's novel live tumor diagnostic platform MADISON, Wis., Sept. 6, 2022 /PRNewswire/ -- Elephas Biosciences Corporation (Elephas), a private company, ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A Madison-based cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results